

Sartorius Stedim Biotech: Share split to become effective May 10, 2016

Aubagne, May 4, 2016 – The split by 6 of the Sartorius Stedim Biotech shares (DIM FP | STDM.PA) and the respective adjustment of the par value per share will become effective May 10, 2016. The share split will be conducted automatically, without any additional costs or formalities for the shareholders and will have no impact on their rights. The operation was approved by the Annual General Shareholders' Meeting (AGM) on April 5, 2016, following a significant increase in the share price over the past two years and aims at increasing the tradability of Sartorius Stedim Biotech shares.

After the split, the share capital of Sartorius Stedim Biotech S.A. will be divided into 92,180,190 shares.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

Contact

Petra Kirchhoff
Vice President Corporate Communications
+49(0)551.308.1686
petra.kirchhoff@sartorius.com

Andreas Theisen
Director Investor Relations
+49(0)551.308.1668
andreas.theisen@sartorius.com